Skip to main content

Table 1 Patient characteristics

From: The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Variable Value
  Number Percent
Age (years)
 Mean 65  
 Range 34–87  
Gender
 Male 78 54
 Female 66 46
Ethnicity
 Asian 1 1
 Caucasian 143 99
Smoking history
 Current smoker 49 34
 Former smoker 85 59
 Never smoker 10 7
ECOG performance statusa
 0 18 12
 1 80 56
 2 37 26
 3 9 6
Tumor type
 Adenocarcinoma 126 88
 Not otherwise specified (NOS) 9 6
 Adenosquamous carcinoma 5 3
 Large cell 3 2
 Adenocarcinoma in situ 1 1
Tumor stage
 IIIA+IIIB 5 3
 IV 139 97
Erlotinib therapy
 First-line 10 7
 Second-line 115 80
 Third-line 14 10
 Fourth-line 5 3
  1. aEastern Cooperative Oncology Group scale to assess how the disease affects the daily living abilities of the patient